Metabolism-based drug interactions involving oral azole antifungals in humans.
Strolin Benedetti
M
M
UCB Pharma SA, Nanterre, France.
Bani
M
M
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D018927:Anti-Asthmatic Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology; D000925:Anticoagulants / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology; D000981:Antiprotozoal Agents / Q000494:pharmacology; D001393:Azoles / Q000494:pharmacology*; D002317:Cardiovascular Agents / Q000494:pharmacology; D002491:Central Nervous System Agents / Q000494:pharmacology; D004347:Drug Interactions; D005765:Gastrointestinal Agents / Q000494:pharmacology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D012076:Renal Agents / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D018927:Anti-Asthmatic Agents; D000890:Anti-Infective Agents; D000925:Anticoagulants; D000935:Antifungal Agents; D000970:Antineoplastic Agents; D000981:Antiprotozoal Agents; D001393:Azoles; D002317:Cardiovascular Agents; D002491:Central Nervous System Agents; D005765:Gastrointestinal Agents; D007004:Hypoglycemic Agents; D012076:Renal Agents